{
    "Trade/Device Name(s)": [
        "COBAS INTEGRA Bilirubin Direct",
        "COBAS INTEGRA Total Bilirubin Special",
        "Roche/Hitachi Total Bilirubin"
    ],
    "Submitter Information": "Roche Diagnostics Corporation",
    "510(k) Number": "K063543",
    "Predicate Device Reference 510(k) Number(s)": [
        "K951595",
        "K981632/A001"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CIG"
    ],
    "Summary Letter Date": "November 22, 2006",
    "Summary Letter Received Date": "November 24, 2006",
    "Submission Date": "October 30, 2006",
    "Regulation Number(s)": [
        "21 CFR 862.1110"
    ],
    "Regulation Name(s)": [
        "Bilirubin (total or direct) test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Bilirubin (total)",
        "Bilirubin (direct)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Lithium heparin sample tube"
    ],
    "Instrument(s)/Platform(s)": [
        "COBAS INTEGRA systems",
        "Roche/Hitachi automated clinical chemistry analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Diazo method"
    ],
    "Methodologies": [
        "Quantitative determination"
    ],
    "Submission Type(s)": [
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for modifications to COBAS INTEGRA and Roche/Hitachi bilirubin (total and direct) test systems for quantitative measurement in serum and plasma.",
    "Indications for Use Summary": "For quantitative determination of total and direct (conjugated) bilirubin in serum and plasma of adults and neonates, aiding in diagnosis of liver, hemolytic hematological, and metabolic disorders.",
    "fda_folder": "Clinical Chemistry"
}